CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Neurorehabilitationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05889169
NCT05889169N/ACompleted

Stroke-induced Immunodepression: Role in the Neurorehabilitation Setting

IRCCS National Neurological Institute "C. Mondino" Foundation·observational·Posted Jun 5, 2023·Updated Jun 5, 2023

In Brief

An observational study evaluating Neurorehabilitation for Stroke and 2 related conditions. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The close interconnection between nervous system and the immune system is well known. Brain injuries lead to homeostasis disruption. On the one hand they result in increased brain inflammation contributing to tissue repair, at the expense of a possible extension of tissue damage. On the other hand, they lead to systemic down-regulation of innate and adaptive immunity, determining higher vulnerability to infections, responsible of death and comorbidities in the acute and subacute setting. Aim of the study was to evaluate the role of immunosuppression in the neurorehabilitation pathway in patients with stroke.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 5, 2023
Enrollment StartFeb 1, 2019
Primary CompletionMay 30, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 3.1 years ago

Interventions

Neurorehabilitationother

Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)